Abstract
Bone disease is a common complication of metastatic solid tumors but also of primary hematological malignancies such as multiple myeloma. Our understanding of the molecular mechanisms underlying the development of bone disease by solid tumors and multiple myeloma has been significantly improved. A complex inter-dependence exists between bone disease and malignant cell growth, creating a vicious cycle of extensive bone destruction and tumor progression. Although myeloma and solid tumors share a number of common molecular pathogenetic mechanisms, they involve distinct pathophysiological pathways, resulting in osteoclastic bone resorption and inhibition of bone formation. In this review, we analyze the molecular mechanisms, involved in tumor-induced bone disease and discuss the current therapeutic approaches and the most recent clinical developments of emerging targeted therapies.
Keywords: Bone disease, cancer, multiple myeloma, molecular targeting, osteoblasts, osteoclasts
Current Medicinal Chemistry
Title: Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Volume: 18 Issue: 11
Author(s): V.T. Labropoulou, A.D. Theocharis, A. Symeonidis, S.S. Skandalis, N.K. Karamanos and H.P. Kalofonos
Affiliation:
Keywords: Bone disease, cancer, multiple myeloma, molecular targeting, osteoblasts, osteoclasts
Abstract: Bone disease is a common complication of metastatic solid tumors but also of primary hematological malignancies such as multiple myeloma. Our understanding of the molecular mechanisms underlying the development of bone disease by solid tumors and multiple myeloma has been significantly improved. A complex inter-dependence exists between bone disease and malignant cell growth, creating a vicious cycle of extensive bone destruction and tumor progression. Although myeloma and solid tumors share a number of common molecular pathogenetic mechanisms, they involve distinct pathophysiological pathways, resulting in osteoclastic bone resorption and inhibition of bone formation. In this review, we analyze the molecular mechanisms, involved in tumor-induced bone disease and discuss the current therapeutic approaches and the most recent clinical developments of emerging targeted therapies.
Export Options
About this article
Cite this article as:
Labropoulou V.T., Theocharis A.D., Symeonidis A., Skandalis S.S., Karamanos N.K. and Kalofonos H.P., Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions, Current Medicinal Chemistry 2011; 18 (11) . https://dx.doi.org/10.2174/092986711795471275
DOI https://dx.doi.org/10.2174/092986711795471275 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones
Anti-Cancer Agents in Medicinal Chemistry Drug Resistance in Childhood Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Epigenetics and Adult Acute Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Preparation and Applications of Superparamagnetic Iron Oxide Nanoparticles in Novel Drug Delivery Systems: An Overview
Current Medicinal Chemistry Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) The Epidemiology of Sepsis
Current Pharmaceutical Design Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents